Finance entity
markets is the sole category represented across all 1 tracked stories. Edgewise Therapeutics is most often covered alongside Ericsson, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Edgewise Therapeutics is most often covered alongside Ericsson, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. We currently track 1 Finance story that mention Edgewise Therapeutics, all published on February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 91 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Edgewise Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Edgewise Therapeutics and Ericsson have both breached 52-week price peaks, signaling robust investor confidence in biotech innovation and telecom infrastructure recovery. While Edgewise benefits from clinical momentum in muscle disease treatments, Ericsson's ascent reflects a stabilized global 5G landscape and a strategic pivot toward AI-native networking.
Edgewise Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
